Catalyst Pharma Receives NASDAQ Deficiency Letter

Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) announced today that it received a Nasdaq Staff Deficiency Letter, dated December 24, 2012, indicating that the Company is not in compliance with the Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The Nasdaq Listing